Experience

Cyclenium Pharma Inc.

• Canada
• Biotechnology Research
• 1 - 100 Employee

• Co-Founder and Principal Scientist

  • Dec 2013 - Present

  My current focus is in on medicinal chemistry using macrocyclic molecules. My current focus is in on medicinal chemistry using macrocyclic molecules.



Cyclenium Pharma Inc

• Principal Scientist

  • Dec 2013 - Present



Independent

• Medicinal Chemistry Consultant

  • Nov 2013 - Present

  Consulting for the Pharma and Biotechnology industry. Consulting for the Pharma and Biotechnology industry.



Tranzyme Pharma

• Principal Scientist

  • Jun 2010 - Nov 2013

  Medicinal Chemistry, Synthetic Organic Chemistry, Peptide Chemistry, Basic Research in Drug Discovery. Medicinal Chemistry, Synthetic Organic Chemistry, Peptide Chemistry, Basic Research in Drug Discovery.



Eliapharma Services inc.

• Canada
• Research Services
• 1 - 100 Employee

• Business Development Director / Drug Discovery Consultant

  • Oct 2009 - Jan 2011

  Current activities: business development, medicinal chemistry consulting, medicinal chemistry. Current activities: business development, medicinal chemistry consulting, medicinal chemistry.



Merck Frosst Canada Ltd.

• Senior Research Fellow

  • Jan 1989 - Sep 2008

  Working with a team of scientists, discovered several drug development candidates for the treatment of Asthma, Chronic Obstructive Pulmonary Disease, Cardiovascular Diseases and Alzheimer Disease. As team member, Singulair for the treatment of asthma was discovered and brought to market. Recent notable achievement was the discovery of Merck's first clinical phosphodiesterase-4 inhibitor L-454,560 which has clinical efficacy for the treatment of asthma. Working with a team of scientists, discovered several drug development candidates for the treatment of Asthma, Chronic Obstructive Pulmonary Disease, Cardiovascular Diseases and Alzheimer Disease. As team member, Singulair for the treatment of asthma was discovered and brought to market. Recent notable achievement was the discovery of Merck's first clinical phosphodiesterase-4 inhibitor L-454,560 which has clinical efficacy for the treatment of asthma.



Merck Frosst Canada Ltd

• Research Fellow

  • Jan 1993 - Jan 2000

• Senior Research Chemist

  • Jan 1989 - Jan 1993



The Ohio State University

• United States
• Higher Education
• 700 & Above Employee

• Post Doctoral Fellow

  • Apr 1987 - Jan 1989

  Synthesis of a natural product molecule under the direction of Professor Leo A. Paquette. Synthesis of a natural product molecule under the direction of Professor Leo A. Paquette.